Recently Introduced Products

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Indication</th>
<th>Potential Impact</th>
<th>Expected Avg. Annual Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Onbrez Breezhaler</td>
<td>For long-term, once-daily, maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema</td>
<td>$</td>
<td>$766.50</td>
</tr>
</tbody>
</table>

$: Est. drug plan expenditure increase of <1%* $$: Est. drug plan expenditure increase of 1-5%* $$$: Est. drug plan expenditure increase of >5%*

Sutent® - A new treatment option for pancreatic neuroendocrine tumors

Sutent® (sunitinib) has been available on the Canadian market since 2006 for the treatment of advanced kidney cancer and for the treatment of GastroIntestinal Stromal Tumours (GIST), a rare cancer of the stomach, bowel, or esophagus. It has most recently been approved by Health Canada to treat a type of pancreatic cancer, known as Pancreatic NeuroEndocrine Tumour (pNET). pNETs are uncommon with an annual incidence of 0.2 per 100,000 population¹. pNET accounts for approximately 1% - 4% of pancreatic cancers.

Currently, there is no single standard of care for patients with pNET. The goal of treatment is to stabilize the tumour and prevent the further spread of cancer to other areas of the body. The majority of patients (>80%) present with metastatic or locally advanced disease i.e. cancer that has spread to other parts of the body. Depending on the size and location of the tumour, surgery is the mainstay treatment. Surgery is curative only for patients presenting with early stage disease. Other treatment options include chemotherapy, radiation and hormone therapy.

Sutent® is an oral drug therapy that belongs to a class of medications called multi-kinase inhibitors. It works by blocking the action of abnormal growth factors that signal cancer cells to multiply². This helps stop or slow the spread of cancer cells and may help shrink the tumour. Sutent® has been approved for pNET when the disease has progressed and cannot be treated with surgery.

For the treatment of pNET, Sutent® is taken once daily. The price for Sutent® is $63.15 per 12.5mg capsule and $126.30 per 25mg capsule. At the recommended dose of 37.5 mg per day, the average daily cost is $189.45. This equates to an approximate annual cost of $69,000.

Currently, Sutent® is placed under Special Authorization for ClaimSecure groups that subscribe to the Managed Formulary, Specialty Drug, and Stop Loss Programs. The Special Authorization criteria will be expanded to include the pNET indication. The Special Authorization process seeks to ensure that: 1) the member is using the therapy as approved by Health Canada 2) coordination of benefits with available provincial public drug programs. For Open Drug Formularies, Sutent® will be fully covered.

If you require additional information about Sutent®, please contact Lavina Viegas, Clinical Pharmacist, Clinical Services Department, at (905) 949-3031 or 1-888-479-7587 ext. 3031.

Recommendation: Special Authorization

ClaimSecure reserves the right to amend in part or in its entirety stated special authorization clinical guidelines

References:

* Based on the Financial Impact Analysis per 100,000 lives covered © 2012 ClaimSecure Inc.